Company news
Galmed Pharmaceuticals Ltd. news in 2024
Galmed Pharmaceuticals Ltd.'s news releases, calls and decks from 2024, newest first.
Sales Agreement Form 6 K
November 14, 2024
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
September 24, 2024
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
September 18, 2024
C/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 Form 6 K
June 5, 2024
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
April 3, 2024
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
March 14, 2024